# HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

> **NCT06149247** · PHASE2 · COMPLETED · sponsor: **Soligenix** · enrollment: 10 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma/Mycosis Fungoides

## Interventions

- **DRUG:** Hypericin
- **DRUG:** Mechlorethamine Topical Gel

## Key facts

- **NCT ID:** NCT06149247
- **Lead sponsor:** Soligenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-05
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-06-27
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149247, "HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06149247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*